XNAS
KYNB
Market cap24mUSD
Oct 08, Last price
5.96USD
1D
-2.77%
1Q
-21.63%
Jan 2017
-72.15%
IPO
-74.97%
Name
FibroGen Inc
Chart & performance
P/E
0.13
P/S
3.74
EPS
45.35
Div yield, %
—
Shrs. gr., 5y
-46.22%
Rev. gr., 5y
-48.42%
Revenues
6m
-78.26%
Net income
183m
P
CFO
-5m
L-96.54%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.
Key people
Thomas B. Neff
Chairman of the Board, Chief Executive Officer, Founder
Pat Cotroneo
Chief Financial Officer, Vice President - Finance · since 2008
Chief Medical Officer · since 2016
Thomas F. Kearns
Lead Independent Director · since 2017
Chief Executive Officer, Director · since 2020
Chairman of the Board · since 2020
Suzanne Blaug
Independent Director · since 2019
Independent Director · since 2015
Independent Director · since 2015
Independent Director · since 2018
Kalevi Kurkijarvi
Independent Director · since 2013
Gerald Lema
Independent Director · since 2017
Independent Director · since 2013
Roberto Pedro Rosenkranz
Independent Director · since 2010
Jorma Routti
Independent Director · since 2013
Julian N Stern
Independent Director · since 2013
Toshinari Tamura
Independent Director · since 2013
Legal address
C/O The Prentice-Hall Corporation System, Inc.
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
Headquarters
409 Illinois Street
San Francisco, CA 94158
US
San Francisco, CA 94158
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||